Answers are grounded in this paper and cite their sources.
Background and Objectives: Metabolic and bariatric surgery improves metabolic dysfunction-associated steatotic liver disease (MASLD), but the hepatocellular carcinoma (HCC) risk that remains after surgery is poorly defined. This narrative review examines how postoperative metabolic improvement and fibrosis regression relate to HCC risk and surveillance. Materials and Methods: A targeted PubMed/MEDLINE search, updated in November 2026, identified clinical studies, mechanistic investigations, and professional guidance. Results: Randomized and paired-biopsy studies show resolution of steatohepatitis and frequent fibrosis regression, but advanced fibrosis persisted in almost half of patients with severe baseline fibrosis in one cohort. Observational studies associate surgery with lower HCC occurrence (pooled incidence 0.05 versus 0.34 per 1000 person-years), mainly in low-risk populations with short follow-up. In the largest biopsy-staged cohort, the benefit to composite liver outcomes came from fewer cirrhosis events and liver-related deaths, with three HCC cases in each group; in compensated cirrhosis, HCC still occurred after surgery. HCC incidence after documented regression of advanced fibrosis or cirrhosis has not been reported, and serum fibrosis scores can fall after surgery for reasons unrelated to fibrosis. Conclusions: Surveillance should follow the best-documented preoperative liver stage and current guidance rather than weight loss alone. Patients with cirrhosis should remain under surveillance, and noncirrhotic F3 fibrosis requires individualized assessment. Stage-specific cohorts reporting HCC separately from composite outcomes are the main research priority.
No takes yet. Share an insight, caveat, or question.
Rzayev et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: